Search Instructions:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Browse Items (1467 total)
-
Creator: the Medical Countermeasures Working Group of the National Ebola Training and Education Center’s (NETEC’s) Special Pathogens Research Network (SPRN)
Subject: Research
Item Type: Publication
Date Last Updated: 2020-08-03
Description: This article is a summary of countermeasures for Marburg virus disease focusing on pathogenesis, clinical features, and diagnostics, with an emphasis on therapies and vaccines that have demonstrated potential for use in an emergency situation,… -
Creator: The Medical Countermeasures Working Group of the National Emerging Special Pathogens Training and Education Center’s (NETEC’s) Special Pathogens Research Network (SPRN)
Subject: Treatment & Care
Item Type: Publication
Date Last Updated: 2021-02-18
Description: This article is one of a series on acute, severe diseases of humans caused by emerging viruses for which there are no or limited licensed medical countermeasures. We approached this summary on South American Hemorrhagic Fevers (SAHF) from a clinical… -
Creator: The Medical Letter on Drugs and Therapeutics
Subject: Treatment & Care
Item Type: Publication
Date Last Updated: 2021-07-15
Description: COVID-19 Vaccine Comparison Chart (online only) effectiveness by vaccine and by variant. -
Creator: the mRNA-1273 Study Group
Subject: Research
Item Type: Publication
Date Last Updated: 2020-07-14
Description: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion… -
Creator: the mRNA-1273 Study Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-06
Description: Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19). -
Creator: The National SARS-CoV-2 Serology Assay Evaluation Group
Subject: Laboratory
Item Type: Publication
Date Last Updated: 2020-09-23
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic in 2020. Testing is crucial for mitigating public health and economic effects. Serology is considered key to population-level surveillance and potentially… -
Creator: the Overcoming COVID-19 Investigators
Subject: Treatment & Care
Item Type: Publication
Date Last Updated: 2021-06-16
Description: The assessment of real-world effectiveness of immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C) may guide therapy. -
Creator: the Oxford COVID Vaccine Trial Group
Subject: Research
Item Type: Publication
Date Last Updated: 2020-12-08
Description: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19… -
Creator: the Oxford COVID Vaccine Trial Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-19
Description: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks. -
Creator: the Oxford COVID-19 Vaccine Trial Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-30
Description: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant.